CompletedNot Applicable

Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease

China40 participantsStarted 2025-01-26

Plain-language summary

The goal of this clinical trial is to learn if ultrasound-guided stellate ganglion block (SGB), added to standard drug treatment, can improve thinking and memory in people with Alzheimer's disease. It will also learn about the safety of SGB. The main questions this study aims to answer are: Do people who receive SGB plus standard drug treatment have better global cognition, measured by the Mini-Mental State Examination (MMSE), 1 month after finishing the treatment course compared with people who receive standard drug treatment alone? How do anxiety, depression, quality of life, and ability to live independently change over 1 month, 3 months, and 6 months after treatment? What medical problems, if any, occur during or after SGB? Researchers will compare two groups: SGB plus standard drug treatment Standard drug treatment alone Participants will: Be randomly assigned to one of the two groups Receive the assigned treatment Complete study visits and assessments at baseline and at 1 month, 3 months, and 6 months after finishing the treatment course

Who can participate

Age range

55 Years – 85 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age 55 to 85 years.
. Diagnosis of Alzheimer's disease (AD) based on the 2011 NIA-AA criteria.
. Mild to moderate cognitive impairment assessed by the Mini-Mental State Examination (MMSE).
. Ability to understand study procedures and provide written informed consent by the participant or a legally authorized representative.
. Ability to complete scheduled follow-up assessments.

Exclusion criteria

. Known allergy to lidocaine, coagulation disorders, or other contraindications to stellate ganglion block (SGB).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Mini-Mental State Examination (MMSE) Total Score

Timeframe: Baseline; Day 20 (end of treatment course); and 1, 3, and 6 months after completion of the treatment course.

Trial details

NCT IDNCT07351773

SponsorTaizhou Second People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-29

View on ClinicalTrials.gov More Alzheimer's Disease(AD) trials